Published: December 11, 2018

Introduction {#sec1}
============

The development of a preventative HIV-1 vaccine is a global health priority. Among the known sites of vulnerability of the HIV-1 envelope glycoprotein (Env), the CD4-binding site (CD4bs) is an appealing target because the requirement for receptor engagement with CD4 limits its variability. VRC01 is a potent CD4bs broadly neutralizing antibody (bnAb) and is the prototype for the VRC01-class of bnAbs ([@bib60], [@bib70], [@bib71], [@bib72], [@bib75], [@bib76]). VRC01-class bnAbs protect animals from experimental HIV-1 or SHIV challenge and can transiently reduce plasma viremia in both non-human primates and chronically HIV-1-infected individuals ([@bib1], [@bib2], [@bib12], [@bib43], [@bib50], [@bib53], [@bib55], [@bib61]). Despite an extraordinary accumulation of somatic mutations, VRC01-class bnAbs adopt similar structures and retain a similar angle of approach to engage the CD4bs ([@bib15], [@bib37], [@bib59], [@bib60], [@bib71], [@bib74], [@bib75], [@bib76]). Moreover, V~H~ allele usage of VRC01-class bnAbs is restricted to V~H~1-2^∗^02, and light chains are restricted to unusually short complementarity-determining region (CDR) L3s of 5 amino acids (aa) ([@bib29], [@bib68], [@bib75]). These predictable characteristics set boundaries useful to guide immunogen design, making the VRC01-bnAb class a particularly attractive target.

The first step to initiate bnAb lineage maturation is to engage naive B cells expressing the unmutated IgH and IgL precursor, referred to as the "unmutated common ancestor" (UCA) of the lineage ([@bib27], [@bib36]). The high levels of somatic hypermutation (SHM) and of insertions and deletions (indels) among the observed members of the VRC01 clone have posed a significant challenge to accurately infer the VRC01 lineage UCA. To design immunogens that engage VRC01-class bnAb unmutated precursors, the field has instead used "germline-reverted" (GL) versions of individual VRC01-class bnAbs in which either the IgH and IgL V gene segments or both the V and J gene segments were reverted to the respective templated germline sequences. Here, we will refer to these GL mAbs as "V.Rev" and "VJ.Rev," respectively. Practically, the GL versions of VRC01-class bnAbs retain the somatically mutated CDR H3s of the mature bnAb of reference. However, the importance of an accurate inference of the CDR H3 is underscored by recent findings indicating that, among VRC01-class bnAb precursors, the CDR H3 plays a more predominant role in HIV-1 gp120 envelope glycoprotein (Env) recognition than once thought ([@bib73]). Nonetheless, this approach has yielded the design of multiple immunogens that bind to GL VRC01-class monoclonal antibodies (mAbs). Gp120 Env outer domain proteins (i.e., eOD-GT6 and eOD-GT8) activate putative VRC01-class B cell precursors in transgenic mice and have been used to isolate putative VRC01 naive B cell precursors from HIV-1-uninfected human subjects ([@bib25], [@bib29], [@bib30], [@bib31], [@bib63], [@bib65]). HIV-1 426c Env-derived core proteins, in which the variable loops 1, 2, and 3 were deleted ([@bib16], [@bib46]), as well as a stabilized BG505 Env-derived SOSIP v4.1-GT1 trimer (referred to as "GT1 trimer" in this paper) ([@bib47]) activate germline-reverted VRC01 B cells in knock-in mice.

For all these immunogens, removal of three glycans that partially occlude the CD4bs was necessary to confer binding to the GL VRC01-class mAbs ([@bib29], [@bib45], [@bib47]). However, the glycan at position N276 in Env D Loop is present in ∼95% of circulating HIV-1 strains and most VRC01-class bnAbs evolved to accommodate the N276 glycan by shortening the germline-encoded CDR L1. Vaccination strategies using progressively glycosylated immunogens have succeeded in eliciting serum antibody responses that can neutralize viruses lacking the N276 glycan site, but not those with the N276 glycan site present ([@bib11], [@bib65]). Hence, the genetic determinants and biological roadblocks hindering the induction of VRC01-class bnAbs that can accommodate the glycan at N276 remain imprecisely defined, suggesting that a detailed VRC01 B cell lineage genealogy is necessary to inform the design of immunogens that will guide lineage maturation toward full neutralization breadth. By inferring the UCA of bnAb lineages with high probability, antibody maturation pathways can be defined that identify biological barriers to the maturation of these lineages toward neutralization breadth. In turn, these analyses can inform immunogen design and vaccination strategies to overcome such barriers ([@bib8], [@bib9]). The challenge of inferring the UCA and maturation intermediate antibodies (IA) of a lineage can be resolved with high probability with a sufficiently large set of clonally related natural heavy (IgH) and light (IgL) chain-paired sequences. Here, we assembled a 45 naturally paired IgH+IgL VRC01 lineage mAbs to reconstruct the VRC01 lineage genealogy, to infer the VRC01 UCA and to identify two different pathways and mechanisms whereby accommodation of the N276 glycan led to broad neutralization.

Results {#sec2}
=======

Inference of the VRC01 UCA {#sec2.1}
--------------------------

To infer the UCA of the VRC01 lineage, we used 45 naturally paired IgH+IgL VRC01 lineage mAbs isolated from memory B cells of NIH donor 45, from whom the VRC01 bnAb was isolated ([@bib70]). Of these, 36 were previously described ([@bib38], [@bib60], [@bib70], [@bib72]) and 9 (DH651.1 through DH651.9) were newly isolated.

The observed members of the clone displayed high levels of SHM and multiple indels, making the inference of the VRC01 UCA substantially more difficult than that of a more typical clone of the same size. The methods available for algorithmic inference of the UCA rely on simplifying assumptions in several components, including the inference of multiple sequence alignment and phylogenetic trees, among others. The lack of appropriate models for insertions and deletions (indels), in particular, made a purely algorithmically computed inference unreliable in the context of the VRC01 lineage. Hence, we combined multiple algorithmic methods and human judgment where it was practically impossible to encode the requisite information into a statistical model. This hybrid method used to infer the VRC01 UCA is described in the [STAR Methods](#sec4){ref-type="sec"}.

The IgH and IgL sequences of the new VRC01 UCA are shown in [Figure 1](#fig1){ref-type="fig"}A. The sum of minimum expected errors over all nucleotides (nt) in the VRC01 UCA V(D)J rearrangements was estimated to be 3.4 nt for IgH and 1.2 nt for IgL. Thus, within the limits associated with any kind of inference, the VRC01 UCA offers an accurate estimate of the unmutated CDR H3 and its evolution through SHM toward the 45 observed mAbs in the lineage.Figure 1VRC01 UCA IgH and IgL Amino Acid Sequences Differed from Those of VRC01 Lineage GL Antibodies(A) VRC01 UCA IgH (top) and IgL (bottom) aa sequences numbered according to the Kabat system ([@bib34]).(B) Ig heavy (top) and light (bottom) chain alignment of VRC01 UCA to VRC01 lineage GL mAbs. The sequence of the mature VRC01 bnAb is shown as reference and mature VRC01 residues involved in interactions with gp120 Env ([@bib74]) are indicated with closed circle.(C) VRC01 UCA CDR H3 aa sequence (positions 95 through 102) aligned to CDR H3s of VRC01 lineage GL mAbs. Cysteines shown in green shade. Differences in CDR H3 length, indels, and aa identity to VRC01 UCA are shown on the right.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

VRC01 UCA CDR H3 and IgL Differ from Those of GL VRC01 Lineage Antibodies Used to Design Immunogens that Target VRC01-Class bnAb Precursors {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------------------------

We aligned VRC01 UCA to five GL VRC01 lineage mAbs ([Figure 1](#fig1){ref-type="fig"}B; [@bib31], [@bib70]). The CDR H3 of the VRC01 UCA was 16 amino acid (aa) long, whereas the length of the V.Rev and VJ.Rev VRC01 lineage mAbs CDR H3s varies from 12 to 16 aa, which reflect indels in the mature mAbs used as reference ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}). CDR H3 aa identities to VRC01 UCA ranged from 19% (VRC06 VJ.Rev) to 63% (NIH45-46 VJ.Rev) ([Figure 1](#fig1){ref-type="fig"}C). The CDR H3 of VRC01 UCA contained two cysteines: Cys98 and Cys100c. Since the arrangement of disulfide bonds can affect the CDR H3 conformation and the stability of VRC01 lineage mAbs ([@bib30], [@bib72]), we compared the positions of cysteines in the VRC01 UCA and the GL mAbs ([Figure 1](#fig1){ref-type="fig"}C). Cys98 is a signature of the VRC01 lineage ([@bib72]) and was conserved in all GL mAbs except VRC01 VJ.Rev. Conversely, Cys100c was not preserved in any of the GL mAbs and it was replaced by an aspartic acid or, in NIH45-46 VJ.Rev, by a serine ([Figure 1](#fig1){ref-type="fig"}C). In the mature VRC01 and NIH45-46 bnAbs, Cys98 forms a disulfide bond with Cys32 (PDB: [3NGB](pdb:3NGB){#intref0010}, [3U7W](pdb:3U7W){#intref0015}) ([@bib15], [@bib70]), which is the result of a mutation in CDR H1 and therefore not present in the VRC01 VJ.Rev and NIH45-46 VJ.Rev mAbs. In VRC01 VJ.Rev, Cys98 has been intentionally mutated to Ser to remove the unpaired cysteine and stabilize the antibody ([@bib30]) whereas in NIH45-46 VJ.Rev, Cys98 remains unpaired (PDB: [4JDV](pdb:4JDV){#intref0020} and [5IGX](pdb:5IGX){#intref0025}) ([@bib59]). In VRC03 VJ.Rev and VRC06 VJ.Rev, Cys98 forms an intra-CDR H3 disulfide bond with Cys100a (PDB: [5JOF](pdb:5JOF){#intref0030}) ([@bib13]), which was introduced by the G100aC mutation in the mature VRC03 and VRC06 mAbs and, as in the mature mAbs (PDB: [3SE8](pdb:3SE8){#intref0035}, [5JXA](pdb:5JXA){#intref0040}, and [4JB9](pdb:4JB9){#intref0045}) ([@bib13], [@bib20], [@bib71]), stabilizes a β-turn at the apex of the CDR H3 loop.

This analysis demonstrated that the Cys98 and Cys100c arrangement of the VRC01 UCA differed from that of all the GL mAbs, which retained the somatically mutated CDR H3s of the mature bnAb of reference. Thus, the observed inter- and intra-CDR H3 disulfide bond shuffling from the VRC01 UCA to the mature VRC01 lineage bnAbs suggested an additional hurdle to the development of breadth.

The VRC01 UCA IgL Vk gene segment sequence differed from the GL mAbs due to variations in the Vk gene segments used as templates for each reversion. The original VRC01 bnAb Vk gene segment assignment was Vk3-11^∗^01 and was later revised to Vk3-20^∗^01 ([@bib70], [@bib75]). Our genealogy analysis supported this later assignment. VRC03 VJ.Rev and VRC06 VJ.Rev were reverted to Vk3-20^∗^01 whereas VRC01 VJ.Rev and VRC01 V.Rev were reverted to Vk3-11^∗^01. NIH45-46 VJ.Rev was instead reverted to Vk3-15^∗^01 ([@bib31]). The GL mAbs not templated on Vk3-20^∗^01 lack Ser31 and, consequently, have shorter CDR L1s. Overall, the light chains of the GL mAbs were more similar to the VRC01 UCA than the heavy chains ([Figure 1](#fig1){ref-type="fig"}B).

These data highlighted the differences between the CDR H3s and light chains of VRC01 UCA and the VRC01 bnAb lineage-derived GL mAbs.

VRC01 UCA Binds to Germline-Targeting Env Forms {#sec2.3}
-----------------------------------------------

Immunogens intended to target VRC01-class bnAb precursors in humans have been designed using VRC01 class GL mAbs to optimize their reactivity and include eOD-GT6 and eOD-GT8 outer domain proteins ([@bib29], [@bib31]), 426c gp120 Env-derived core proteins TM1ΔV1-3 (also reported as 426c degly3) and TM4ΔV1-3 cores ([@bib45], [@bib46]), C13 gp120 core ([@bib65]), and the GT1 trimer ([@bib47]). To assess the ability of these six Env immunogens to bind to VRC01 UCA, we measured the binding kinetics of VRC01 UCA and compared it to nine GL VRC01-class mAbs derived from VRC01-class bnAbs (isolated from multiple individuals) ([Table S1](#mmc1){ref-type="supplementary-material"}). eOD-GT8 and eOD-GT6 bound to VRC01 UCA with apparent dissociation constants (K~D~) of \<0.1 nM and 2.4 μM, respectively ([Figure 2](#fig2){ref-type="fig"}A). eOD-GT8 had the most favorable apparent affinity for all the mAb tested (K~D~ range: \<0.1 nM--0.3 μM) and displayed strong affinity for VRC01 UCA (K~D~ = 0.25 nM). eOD-GT6 bound with 10,000-fold weaker affinity (K~D~ = 2.5 μM). The GT1 trimer bound to 5 of 9 GL mAbs (apparent K~D~ range: 3.7 nM--0.18 μM) and also bound to VRC01 UCA, albeit with much weaker affinity than eOD-GT8 (apparent K~D~ = 3 μM). While the GT1 trimer apparent affinity to VRC01 UCA was comparable to that of eOD-GT6, it was likely overestimated due to the potential avidity effect of the trimeric configuration of GT1. TM1ΔV1-3, TM4ΔV1-3, and C13 core proteins bound to four, seven, and three GL mAbs, respectively, but did not bind to VRC01 UCA ([Figure 2](#fig2){ref-type="fig"}A).Figure 2VRC01 UCA Bound to Immunogens Designed of GL VRC01-Class mAbs(A) VRC01 UCA (red) and GL VRC01-class mAbs (black) dissociation constants against six immunogens. Each data point shows the average of at least duplicate experiments. mAbs that did not display measurable binding are shown with K~D~ \> 100 μM.(B) On-rates (x-axis) and off-rates (y-axis) for the same mAbs and immunogens. Only mAbs with K~D~ \< 100 μM are shown.(C) B cell activation mediated by immunogens (red) measured by calcium flux (y-axis) on Ramos B cells expressing VRC01 UCA IgM BCR over 300 s (x-axis). Immunogen mutants with either D279K/D368R or D268R/E370A double mutation are shown in black ("KO mutants"). For the GT1 trimer, BG505 SOSIP was used as KO mutant. Results are expressed as percentage of the maximum signal obtained with an anti-IgM F(ab)~2~ antibody and are representative of at least duplicate experiments.(D) Binding of monomeric (left), heptameric (middle), and icositetrameric (right) TM4ΔV1-3 core (green) and eOD-GT8 (blue) to VRC01 UCA IgG. KO mutants are shown with dotted lines. Results are representative of duplicate experiments.See also [Table S1](#mmc1){ref-type="supplementary-material"}, [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Differences in eOD-GT8 apparent affinities were mainly driven by variations in off-rates (k~off~), which spanned 3 orders of magnitude (k~off~ range: \< 0.01--25.92 ms^−1^) ([Figure 2](#fig2){ref-type="fig"}B). The fast on-rate (k~on~) and slow k~off~ of eOD-GT8 for VRC01 UCA indicated that eOD-GT8 not only optimized the complementarity for the cognate antigen but also stabilized the complex. eOD-GT6 displayed slower k~on~ and faster k~off~ than eOD-GT8 for VRC01 UCA and bound to most of the GL mAbs better than to VRC01 UCA. The GT1 trimer on- and off-rates for VRC01 UCA were faster than eOD-GT6 (k~on~ = 8,000 M^−1^s^−1^ versus 3,000 M^−1^s^−1^; k~off~ = 0.018 s^−1^ versus 0.068 s^−1^, respectively), suggesting better GT1 trimer complementarity for VRC01 UCA but a less stable GT1:VRC01 UCA complex than eOD-GT6, despite the more favorable avidity effect of its trimeric conformation ([Figure 2](#fig2){ref-type="fig"}B).

Since the first step to elicit bnAbs is to activate naive B cell precursors by engaging the IgM B cell receptor (BCR), we constructed a Ramos B cell line expressing transmembrane VRC01 UCA IgM on the cell surface and measured the ability of the immunogens to mediate Ca^2+^ flux. All Env forms were biotinylated and tetramerized on streptavidin to optimize BCR cross-linking ([@bib49]). eOD-GT8 displayed superior activation of VRC01 UCA IgM BCR-expressing B cells (peak % response of maximum αIgM binding: 72.3%), which was \>3-fold higher than that of eOD-GT6 (peak response: 22.2%) ([Figure 2](#fig2){ref-type="fig"}C). As a multimer, the GT1 trimer activated B cells more efficiently than the tetrameric form of eOD-GT6 (peak response: 56.2%), possibly because of a combination of faster on-rate and higher degree of multimerization ("tetramer of trimers") ([Figure 2](#fig2){ref-type="fig"}C). The tetramerized TM1ΔV1-3 activated IgM BCR-expressing B cells (peak response: 22.4%) despite not binding to VRC01 UCA IgG in monomeric form, whereas C13 core proteins and tetrameric TM4ΔV1-3 did not induce Ca^2+^ flux ([Figure 2](#fig2){ref-type="fig"}C). Further multimerization improved eOD-GT8 binding to VRC01 UCA IgG and conferred upon TM4ΔV1-3 binding to VRC01 UCA IgG ([Figure 2](#fig2){ref-type="fig"}D). Moreover, heptamerization of TM4ΔV1-3 was sufficient to induce activation of VRC01 UCA IgM BCR-expressing B cells (peak response: 38.2%) ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Thus, multimerized eOD-GT8, GT1 trimer, TM1ΔV1-3, and TM4ΔV1-3 activated Ramos cells expressing VRC01 UCA IgM BCR. The different kinetics between VRC01 UCA and the GL mAbs highlighted the impact of CDR H3 on the recognition of VRC01 class naive precursors. Overall, the Env outer domain proteins (eOD-GT6, eOD-GT8) were less sensitive to differences in CDR H3. In fact, human naive B cells isolated with eOD-GT8 yielded mAbs with a variety of CDR H3 lengths and aa compositions ([@bib31]) that substantially differed from VRC01 UCA, with the closest Ab reaching only 50% identity to the VRC01 UCA CDR H3 ([Figure S3](#mmc1){ref-type="supplementary-material"}). Also, CDR H3 length has only a modest impact on naive VRC01-class B cells affinity for eOD-GT8 ([@bib25]). Similarly, stepwise immunization with eOD-GT6, progressively glycosylated 426c core proteins, and 426c-WT SOSIP of ES cell mice in which V~H~1-2^∗^02 and precursor VRC01 IgL were knocked in ([@bib65]) elicited mAbs with CDR H3 sequences substantially different from that of VRC01 UCA ([Figure S3](#mmc1){ref-type="supplementary-material"}). Despite differences in murine and human D and J~H~ segment repertoires, on average, CDR H3 aa identity to VRC01 UCA was comparable among the two studies (21.5% for human B cells versus 20.5% for the murine B cells) ([Figure S3](#mmc1){ref-type="supplementary-material"}). Thus, the Env outer domain proteins bound unequivocally well to VRC01 UCA. However, while eOD-GT8 engages VRC01-class naive B cells in humans, its reactivity is not exclusive to this class ([@bib25]); hence, in the context of a stepwise immunization regimen, subsequent immunogens need be engineered to promote focusing of the B cell response and steer clonal evolution toward maturation pathways that will more likely result in the development of neutralization breadth.

Early Mutations Defined Maturation Pathways with Either Broad or Limited Neutralization {#sec2.4}
---------------------------------------------------------------------------------------

The reconstruction of the VRC01 genealogy from the UCA and the inference of the unobserved maturation intermediate antibodies (IA) confirmed that the VRC01 B cell lineage evolved into three divergent clades (clade 03+06, clade 08, and clade 01+07), as previously reported ([@bib72]), and enabled to map the stages of clonal evolution at which clade-defining mutations occurred ([Figure 3](#fig3){ref-type="fig"}). The three clades diverged early during clonal maturation: clade 03+06 diverged from clades 01+07 and 08 at the first node (IA1), and clade 01+07 diverged from clade 08 at the subsequent node (IA2) ([Figure 3](#fig3){ref-type="fig"}). IA1 mutated 25 aa and IA2 further accumulated 9 aa mutations. Each clade further acquired distinct sets of indels in framework region (FR) H3, CDR H3, and CDR L1. Clade 03+06 inserted 21 nt at position 216 in FR H3 (IA5 node in [Figure 3](#fig3){ref-type="fig"}). Since FR H3 contacts the gp120 V1/V2 stem region, this insertion may render clade 03+06 mAbs more sensitive to variations in the Env V1/V2 loop ([@bib74]). The maturation of CDR H3 and CDR L1 are shown in [Figure 4](#fig4){ref-type="fig"}. CDR H3 underwent extensive modifications in all three clades and 80% of the mature mAbs introduced indels in this region. In clade 03+06, Asp100e and Trp100f were deleted. Trp100f is positioned 5 aa prior to the start of FR H4 and corresponds to Trp100b in the VRC01 bnAb aa sequence, which has been reported to be important for neutralization ([@bib68]). Our reconstruction indicated that Trp100f was the result of the primary V-D-J recombination, not affinity maturation ([Figure 4](#fig4){ref-type="fig"}). Encouragingly, VRC01-class naive B cells with Trp100f can be sampled from the human naive B cell repertoire and enriched for using eOD-GT8 as a bait ([@bib25]). Sub-clade 06 inserted an additional serine at position 96 in CDR H3, which further mutated to Pro96 within the sub-clade. mAbs in sub-clade 07 did not introduce indels in CDR H3. Conversely, sub-clade 01 mAbs deleted 12 nt resulting in the deletion of the ^99^SGGS^100b^ aa motif and the C100cD mutation, which eliminated the inter-CDR H3 disulfide bond with Cys98 and formed the Env-contacting DYN motif ([@bib74]). Clade 08 mAbs introduced a 21-nt duplication which resulted in a 23-aa long CDR H3. Finally, clade-specific deletions developed in CDR L1, which interfaces with the Env N276 glycan: clade 03+06 mAbs deleted the aa ^28^VS^29^ (IA5 node), and clade 01+07 mAbs similarly deleted ^28^VSS^30^ at the IA3 node. CDR L1 aa sequences did not cluster within subclades as precisely as the CDR H3s. Notably, the CDR L1 of clade 08 mAbs did not acquire deletions ([Figure 4](#fig4){ref-type="fig"}).Figure 3VRC01 Phylogeny from the VRC01 UCA Detailed the Maturation Pathways of VRC01 Lineage AntibodiesVRC01 phylogeny reconstructed from 45 mAbs with natural paired IgH and IgL sequences. Inferred maturation intermediate antibodies IA1 through IA6 are colored based on clade membership (right). Indels (aa) are mapped on the tree. Units of branch-length estimates are nt substitutions per site.Figure 4CDR H3 and CDR L1 Maturation Was Divergent across VRC01 Lineage CladesAlignment of CDR H3 (left) and CDR L1 (right) aa sequences of the observed VRC01 lineage mAbs to the VRC01 UCA sequence (green). Sequences are grouped by clade and subclade membership. mAbs are listed by their respective sequences. mAbs with sequences that clustered outside their subclade membership are indicated with an asterisk.

The neutralizing activity of VRC01 UCA and the 45 mature mAbs was assessed on a panel of 12 HIV-1 strains representative of the global diversity ([@bib14]). VRC01 UCA did not neutralize any of the viruses tested (IC~50~ \> 50 μg/mL). Clades 01+07 and 08 bnAbs displayed comparable breadth (geometric mean: 86% and 89%, respectively; median: 91.7% for both clades) whereas clade 03+06 mAbs were significantly narrower (geometric mean: 51%; median: 58.3%, p \< 0.01), especially subclade 06 (geometric mean: 35%; median: 41.7%) ([Figure 5](#fig5){ref-type="fig"}A, [Table S2](#mmc1){ref-type="supplementary-material"}). Only 26% of the strains were neutralized by clade 03+06 mAbs with IC~80~ \< 50 μg/mL versus 79% and 73% for clade 01+07 and clade 08 mAbs, respectively ([Table S3](#mmc1){ref-type="supplementary-material"}). Interclade differences in potency were less pronounced (geometric mean IC~50~ = 0.74 μg/mL, 0.68 μg/mL, and 2.4 μg/mL for clades 01+07, 08, and 03+06, respectively), with subclade 06 also comprising the least potent mAbs (geometric mean IC~50~ = 10.5 μg/mL) ([Figure 5](#fig5){ref-type="fig"}B).Figure 5VRC01+07 and VRC08 Clade Antibodies Acquired Broad Neutralization whereas VRC03+06 Antibodies Displayed Limited Neutralization Breadth(A) Neutralization was measured against the 12-virus global panel and expressed as percentage (y-axis). mAbs were grouped by clade membership: 16 in clade 03+06, 4 in clade 08, and 23 in clade 01+07. Subclade 06 mAbs are shown as clear dots. Lines indicate geometric mean. Results are representative of duplicate observations. Significance was evaluated using Kruskal-Wallis and Dunn's multiple comparisons tests at the alpha 0.05 level.(B) Neutralization potency (IC~50~) expressed in μg/mL (y-axis). Differences in potency across clades were not statistically significant.See also [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.

Thus, we identified maturation pathways off-track (clade 03+06) and on-track (clades 01+07 and clade 08) toward broad neutralization with clade 03+06 branching out at the earliest inferred intermediate (IA1). This finding suggested that a successful vaccine may need to focus early clonal maturation ("clade focusing") on track toward clades with the broadest neutralization. The VRC01 genealogy also informed the design of immunogens targeting early maturation IAs to select for mutations on-track toward the broadest clades (i.e., 01+07 and 08) and against mutations that define the 03+06 off-track VRC01 maturation pathway. These data also demonstrated that CDR L1 shortening alone was neither an absolute requirement (e.g., VRC08) nor sufficient (e.g., VRC01 lineage antibody DH651.8) to confer broad neutralization in the VRC01 lineage ([Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}).

Heavy Chain, Not CDR L1, Is the Determinant to Accommodate the N276 Glycan in VRC08 Clade Antibodies {#sec2.5}
----------------------------------------------------------------------------------------------------

It is widely recognized that VRC01-class bnAbs evolved to accommodate the Env glycan at position N276 by either shortening or increasing the flexibility of their CDR L1 through SHM. The induction of robust VRC01-class antibody responses recognizing Envs with the N276 glycan remains, to date, elusive. Here we showed that, within the VRC01 lineage, clade 01+07 and clade 03+06 mAbs shortened their CDR L1 whereas clade 08 did not. To understand how VRC08 compensated for the suboptimal interaction between its CDR L1 and the HIV-1 Env N276 glycan, we superposed the VRC08 structure (PDB: [4XMP](pdb:4XMP){#intref0050}) ([@bib72]) onto VRC01 in the JR-FL SOSIP complex (PDB: [5FYK](pdb:5FYK){#intref0055}) ([@bib64]) ([Figures 6](#fig6){ref-type="fig"}A and 6B). The VRC08 epitope size on the trimer was increased by ∼50% ([Figure 6](#fig6){ref-type="fig"}A) compared to VRC01 ([Figure 6](#fig6){ref-type="fig"}B), largely due to the increased contact surface accounted for by the elongated CDR H3, as previously noted for the gp120 monomeric complex ([@bib72]).Figure 6Heavy Chain, Not CDR L1, Is the Determinant to Accommodate the N276 Glycan in VRC08 bnAb and Initiate Breadth(A) Superposition of the VRC08 structure onto the JRFL SOSIP structure in complex with VRC01. Coloring scheme is as follows: heavy chain (blue), light chain (gray), CDR H3 (red), CDR H3 contact surface (cyan), gp120s (green shades), and gp41s (orange shades). Glycans are shown in stick representation. The N301 glycan was removed from the view for clarity.(B) Structure of VRC01 in complex with JR-FL SOSIP used to superpose VRC08, with same color scheme of (A).(C) Heat map analysis of neutralization data of VRC01 UCA, VRC08~H~/UCA~L~ chimera, and mature VRC08 bnAb (columns) against the 426c wild-type HIV-1 strain and its N276D mutant (in which the potential N-linked glycosylation site at position 276 was abrogated) and the 12-virus global panel. MLV-SVA is shown as negative control. Neutralization potency IC~50~ is expressed in μg/mL and coloring ranges from white (\>50 μg/mL) to dark red (\<0.023 μg/mL). Results are representative of at least duplicate experiments.See also [Figure S4](#mmc1){ref-type="supplementary-material"}, [Videos S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.

To determine the relative stability of the VRC08 CDR H3 conformation in the putative VRC08 SOSIP-bound state, we performed a 50 ns molecular dynamics simulation of VRC08 Fab bound to each protomer in a glycosylated JR-FL SOSIP trimer. The average backbone root-mean square deviation (RMSD) of the three individual CDR H3 loops were 1.4 ± 0.1 Å, 1.6 ± 0.2 Å, and 1.6 ± 0.2 Å, indicating that the loops remained stable in a state similar to that of the gp120-bound crystal structure configuration (PDB: [4XMP](pdb:4XMP){#intref0060}) ([@bib72]) during the simulation ([Figure S4](#mmc1){ref-type="supplementary-material"} and [Video S1](#mmc2){ref-type="supplementary-material"}). We investigated the interface between Env N276 glycan and CDR L1 for each protomer. Throughout the simulation, the average minimum and maximum distances between the N276 α-carbon and the CDR L1 α-carbon centers of geometry were ∼10.0 Å and ∼13.5 Å, respectively, with average distances of 12.3 ± 0.5 Å, 11.3 ± 0.7 Å, and 12.2 ± 0.5 Å for each protomer. Since CDR L1s were in close contact with the N276 residues, the conformation space available to the glycans was severely limited. However, the relatively narrow distance distribution between N276 and the CDR L1 in each protomer indicated that the CDR L1 loop conformation was stable throughout the simulation ([Video S2](#mmc3){ref-type="supplementary-material"}). The N276 glycosylation site is predominantly occupied by minimally processed glycans (e.g., Man~5-9~GlcNAc~2~) in the context of trimeric SOSIP ([@bib3]); however, occupancy by complex glycans among naturally occurring virions may further reduce the solutions available to VRC01-class bnAbs with longer CDR L1, even though the ability of VRC08 to broadly and potently neutralize implies that unfavorable solutions on virions represent only a minority of cases.

Video S1. Molecular Dynamics Simulation of the VRC08 CDR H3 Interaction with the HIV-1 Env, Related to Figure 6View facing the JR-FL SOSIP trimer (purple/yellow/white/cyan) apex with the three bound VRC08 (orange) Fabs. Despite domain scale motion at the Fab elbow and in the relative dispositions of the gp120 protomers to one another, the VRC08 CDR H3 (green surface) and CDR L1 (blue surface) interaction sites remain in their initial bound conformations.

Video S2. Molecular Dynamics Simulation of the VRC08 CDR L1 Interaction with the HIV-1 Env N276 Glycan, Related to Figure 6Representative view of the VRC08 (orange) interaction with the JR-FL SOSIP trimer (purple/yellow/white/cyan) depicting the close interaction between CDR L1 (blue surface) and the N276 glycan (red surface). Monitoring of the relative distance between the CDR L1 loops and the N276 bases in each Fab-protomer interaction indicates the bound state positions in each VRC08 Fab were stable throughout the simulation. The VRC08 CDR H3 (green surface) and additional glycans (transparent gray) are shown for reference and clarity.

The mature VRC08 CDR L1 was highly mutated (6 of 7 aa) and we sought to determine whether these mutations were responsible for accommodating the N276 glycan. We produced a chimeric antibody pairing VRC08 IgH with VRC01 UCA IgL (VRC08~H~/UCA~L~). VRC08~H~/UCA~L~ neutralized the fully glycosylated and the N276D mutant HIV-1 426c strain comparably (IC~50~ = 0.71 μg/mL and 0.11 μg/mL, respectively) ([Figure 6](#fig6){ref-type="fig"}C). Moreover, VRC08~H~/UCA~L~ retained 50% of neutralization breadth of the mature VRC08 bnAb ([Figure 6](#fig6){ref-type="fig"}C). Thus, the CDR L1 mutations in the mature VRC08 bnAb, while beneficial to breadth, were not essential to accommodate the N276 glycan. These data demonstrated that VRC01-class bnAb precursors can circumvent the barrier posed by the N276 glycan to initiate broad neutralization by using IgH chains with a long CDR H3 without the need of mutating or shortening the germline-encoded CDR L1. We hypothesize that the CDR H3 elongation in VRC08 leads to an increase in enthalpy due to expanded epitope contacts. This enthalpy increase then could compensate for the entropy penalty associated with trapping the N276 glycan in a limited number of accommodating conformations without requiring a deletion in CDR L1. Thus, the preferential engagement of VRC01-class naive B cells with long CDR H3s may be an alternative strategy to overcome the N276 glycan barrier.

VRC01 Lineage mAbs Do Not Need to Be Auto- or Polyreactive to Broadly Neutralize {#sec2.6}
--------------------------------------------------------------------------------

VRC01 lineage bnAbs can be either polyreactive or autorective with Ubiquitin Protein Ligase E3A (UBE3A) ([@bib41]) and studies in GL VRC01-class 3BNC60 knock-in mice suggested that VRC01 class bnAb precursors may be regulated by tolerance mechanisms ([@bib46]). We measured auto- and polyreactivity of the VRC01 UCA, GL VRC01-class mAbs, and the 45 naturally paired IgH+IgL mature VRC01 lineage mAbs. VRC01 UCA was not auto- or polyreactive ([Figure S5](#mmc1){ref-type="supplementary-material"}). In comparison, 4 of 9 GL VRC01-class mAbs were self-reactive: VRC01 V.Rev was at the threshold for polyreactivity; VRC18b V.Rev displayed a cytoskeleton pattern in HEp2 cell IFA staining; and VRC20 V.Rev and VRC23 V.Rev were polyreactive, displayed cytoplasmic IFA staining, and bound, respectively, to centromere B and all nine autoantigens ([Figure S5](#mmc1){ref-type="supplementary-material"}). Notably, VRC01 V.Rev, VRC18b V.Rev, and VRC20 V.Rev were among the mAbs with the most favorable binding kinetics for the immunogens designed on GL mAbs. Of the 45 mature VRC01 lineage mAbs, 36 (80%) were self-reactive ([Figure 7](#fig7){ref-type="fig"}A). However, non-auto or polyreactive mAbs neutralized as broadly and potently as the auto-/polyreactive ones ([Figures 7](#fig7){ref-type="fig"}B and 7C). Non-auto or polyreactive mAbs were distributed across the three VRC01 lineage clades and included the VRC08 bnAb, which was as broad and potent as the VRC01 bnAb. There was no correlation between neutralization breadth and potency versus polyreactivity at the alpha 0.05 level (Spearman correlation: −0.2896 and 0.2003, respectively; p \> 0.05) ([Figures 7](#fig7){ref-type="fig"}D and 7E).Figure 7Lack of Relationship between Auto- and Polyreactivity and Neutralization Breadth in Mature VRC01 Lineage bnAbs(A) UBE3A reactivity (red), polyreactivity (blue), and anti-nuclear antigens (ANA) autoreactivity are shown for each mAb.(B and C) Neutralization breadth (B) and potency (C) of non-auto-/polyreactive (n = 9) and auto-polyreactive (n = 34) antibodies as defined in (A). Significance was evaluated with the Mann-Whitney U test at the alpha 0.05 level.(D and E) Lack of correlation between neutralization breadth (D) or potency (E) and polyreactivity.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

UBE3A-reactive mAbs clustered exclusively in clade 01+07 and represented the majority of mAbs in this clade (19/24; 79.2%). We noted that the germline-encoded ^33^YM^34^ motif in CDR H1 mutated in all 45 mature mAbs and that subclade 01 predominantly mutated to ^33^TL^34^ ([Figure S6](#mmc1){ref-type="supplementary-material"}A). mAbs with ^33^TL^34^ were significantly more reactive with UBE3A (p \< 0.001; [Figure S6](#mmc1){ref-type="supplementary-material"}B). Reversion of ^33^TL^34^ to the germline-encoded ^33^YM^34^ in subclade 01 VRC01, VRC02, DH651.1, DH651.2, and DH651.4 bnAbs abrogated UBE3A reactivity ([Figure S6](#mmc1){ref-type="supplementary-material"}C). mAbs with reversion mutations that restored the germline-encoded YM motif retained full breadth with a modest (1.4- to 2.7-fold) reduction in potency ([Figure S6](#mmc1){ref-type="supplementary-material"}D). We introduced the T33Y and L34M reversion mutations separately in VRC01: their neutralization profiles were comparable to that of the double ^33^YM^34^ mutation ([Figure S6](#mmc1){ref-type="supplementary-material"}D) and, while the single L34M reversion mutation did not affect VRC01 binding to UBE3A, T33Y was sufficient to abrogate VRC01 bnAb UBE3A reactivity ([Figure S6](#mmc1){ref-type="supplementary-material"}E). The Y33T mutation was estimated to be improbable (Y33T probability \< 1% versus 28.5% of M34L; [Figure S6](#mmc1){ref-type="supplementary-material"}F) ([@bib69]), and since Tyr33 interacts with HIV-1 envelope protein gp120 ([@bib74]), the Y33T mutation was likely the result of strong antigen-driven positive selection in subclade 01 mAbs.

Thus, these data demonstrated that VRC01 UCA is not auto- or polyreactive and that acquisition of auto-/polyreactivity by VRC01 lineage mAbs was not a requirement for development of neutralization breadth.

Discussion {#sec3}
==========

The lack of accurate reconstructions of the paired IgH and IgL genealogy of VRC01-class bnAb lineages from their UCA has posed substantial hurdles in devising strategies to identify and overcome roadblocks that impede the elicitation of VRC01-class bnAbs through vaccination. Here we have described the inference of the UCA of the VRC01 lineage and reconstructed the stages of the VRC01 lineage maturation.

We demonstrated that existing Env immunogens designed on GL VRC01-class bnAbs bound to VRC01 UCA with affinity sufficient to activate naive B cells; that early clade focusing led to maturation pathways on- and off-track to broad neutralization; and that solutions to breadth exist that did not require shortening or increased flexibility of the CDR L1 to accommodate the Env N276 glycan.

Reproducing consistently the complex evolution of the VRC01 lineage described here (including the acquisition of extensive SHM and indels) in its entirety through vaccination is likely to be challenging. In particular, if and how the frequency of indels can be manipulated through vaccination is unknown and future studies should explore strategies to address this issue. However, our observations indicated possible alternative maturation end points that may suffice to induce or initiate the development of VRC01-class bnAbs. Inducing the maturation of VRC01-class bnAbs from unmutated precursors that can neutralize HIV-1 strains with the N276 glycan site remains a critical barrier for vaccine development. While clade 01+07 circumvented this barrier by shortening CDR L1, clade 08 mAbs retained normal-length CDR L1s and mutated their IgH with a large insertion in CDR H3. This observation raised the hypothesis that, among VRC01-class bnAb precursors with longer CDR H3 in the naive B cell repertoire, at least some will naturally bypass the N276 glycan barrier and may more readily progress to breadth. Interestingly, [@bib25] have recently demonstrated a modest inverse correlation between CDR H3 length and affinity of naive VRC01-class B cells to eOD-GT8, which may result in a suboptimal engagement of this subpopulation of naive B cells in presence of naive VRC01-class B cells with shorter CDR H3s. Since long CDR H3s are typically the result of the original V~H~DJ~H~ recombination and antibodies using the V~H~1 gene family are naturally skewed toward primary rearrangements with long CDR H3 ([@bib10]), future studies should investigate whether this subpopulation of VRC01-class precursors can be preferentially targeted through immunogen design.

Three distinct maturation pathways in the VRC01 lineage diverged early during clonal development, leading to either relatively limited (clade 03+06) or broad (clades 01+07 and 08) neutralization. That most of clade 03+06 mAbs acquired SHM leading to limited neutralization breadth emphasizes that breadth is not an end point of lineage maturation in natural infection and we speculate that, due to the polyreactive nature of the VRC01 lineage, the process of antibody redemption may have also contributed to shape its evolution ([@bib54], [@bib57]). Previous immunization strategies may have failed to effectively focus maturation to the desired potently neutralizing clades at the earliest stages of clonal maturation. This study identified limited sets of early, clade-defining mutations that provide a roadmap to design immunogens that will guide the selection of early intermediates on-track toward neutralization breadth ([@bib69]). Possible end points of VRC01 maturation resulting in the acquisition of various levels of neutralization breadth with limited SHM have been described ([@bib21], [@bib32]). Of them, a mAb referred to as minVRC01 reaches 84% breadth with 21 amino acid mutations, far fewer than the 69 aa mutations in VRC01 bnAb (excluding mutations in CDR H3 and the CDR L1 deletion) ([@bib32]). However, this was achieved starting from a mature CDR H3 and a shortened CDR L1, which is a rate-limiting maturation event. In addition, 15 of the 21 aa mutations in minVRC01 are improbable (unpublished data), suggesting that the pathway to minVRC01 will be challenging to elicit. Together with new computational tools that assign the probability of specific mutations throughout clonal maturation ([@bib69]), the VRC01 genealogy described here enables a more precise definition of the most efficient routes to neutralization breadth in the VRC01 lineage. Antibody mutations occur with varying frequencies prior to selection due to the stochastic nature of the SHM process ([@bib5], [@bib51], [@bib66]) and, while the detailed genealogy provides a map of the mutational routes, information about the probabilities of mutations prior to immunogenic selection along those routes helps in defining how difficult (or easily) these mutations can be selected. Beneficial mutations that are probable should be readily available in germinal centers due to normal immune activation. Conversely, beneficial improbable mutations require strong selective pressure to arise during SHM and can act as bottlenecks in the development of bnAbs ([@bib9]). Mutations detrimental to neutralization can be barriers to bnAb lineage development as well and, if detrimental mutations are also highly probable, they can act as diverting forces for B cell maturation, directing a component of a clone off-track. The implications for vaccine development are that critical improbable mutations represent the highest value targets for selection in vaccine design strategies and, concurrently, detrimental probable mutations may need to be selected against.

In conclusion, the reconstruction of the VRC01 lineage UCA, the higher level of detail of the routes to neutralization breadth through the newly reconstructed VRC01 genealogy, and a better understanding of the probabilities of individual mutations in the lineage ([@bib69]) provide a valuable dataset to design immunogens that will efficiently select for B cell maturation pathways leading to broad neutralization.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**VRC03 g (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840675](ncbi-n:KP840675){#intref0065}, [KP840706](ncbi-n:KP840706){#intref0070}VRC03 (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [GU980706](ncbi-n:GU980706){#intref0075}, [GU980707](ncbi-n:GU980707){#intref0080}; RRID: [AB_2491021](nif-antibody:AB_2491021){#intref0085}VRC03b (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840671](ncbi-n:KP840671){#intref0090}, [KP840702](ncbi-n:KP840702){#intref0095}VRC03f (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840674](ncbi-n:KP840674){#intref0100}, [KP840705](ncbi-n:KP840705){#intref0105}VRC03e (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840673](ncbi-n:KP840673){#intref0110}, [KP840704](ncbi-n:KP840704){#intref0115}VRC03i (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840677](ncbi-n:KP840677){#intref0120}, [KP840708](ncbi-n:KP840708){#intref0125}VRC03h (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840676](ncbi-n:KP840676){#intref0130}, [KP840707](ncbi-n:KP840707){#intref0135}VRC03d (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840672](ncbi-n:KP840672){#intref0140}, [KP840703](ncbi-n:KP840703){#intref0145}VRC06b (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib38])GenBank: [JX466925](ncbi-n:JX466925){#intref0150}, [JX466926](ncbi-n:JX466926){#intref0155}VRC06d (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840679](ncbi-n:KP840679){#intref0160}, [KP840710](ncbi-n:KP840710){#intref0165}VRC06 g (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840682](ncbi-n:KP840682){#intref0170}, [KP840713](ncbi-n:KP840713){#intref0175}VRC06e (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840680](ncbi-n:KP840680){#intref0180}, [KP840711](ncbi-n:KP840711){#intref0185}VRC06f (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840681](ncbi-n:KP840681){#intref0190}, [KP840712](ncbi-n:KP840712){#intref0195}VRC06 (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib38])GenBank: [JX466923](ncbi-n:JX466923){#intref0200}, [JX466924](ncbi-n:JX466924){#intref0205}VRC06c (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840678](ncbi-n:KP840678){#intref0210}, [KP840709](ncbi-n:KP840709){#intref0215}VRC08e (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840687](ncbi-n:KP840687){#intref0220}, [KP840718](ncbi-n:KP840718){#intref0225}VRC08c (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840685](ncbi-n:KP840685){#intref0230}, [KP840716](ncbi-n:KP840716){#intref0235}VRC08d (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840686](ncbi-n:KP840686){#intref0240}, [KP840717](ncbi-n:KP840717){#intref0245}VRC08 (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840684](ncbi-n:KP840684){#intref0250}, [KP840715](ncbi-n:KP840715){#intref0255}VRC02 (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [GU980704](ncbi-n:GU980704){#intref0260}, [GU980705](ncbi-n:GU980705){#intref0265}; RRID: [AB_2491020](nif-antibody:AB_2491020){#intref0270}VRC01c (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840658](ncbi-n:KP840658){#intref0275}, [KP840689](ncbi-n:KP840689){#intref0280}VRC01g (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840662](ncbi-n:KP840662){#intref0285}, [KP840693](ncbi-n:KP840693){#intref0290}VRC01b (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840657](ncbi-n:KP840657){#intref0295}, [KP840688](ncbi-n:KP840688){#intref0300}VRC01 (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [GU980702](ncbi-n:GU980702){#intref0305}, [GU980703](ncbi-n:GU980703){#intref0310}; RRID: [AB_2491019](nif-antibody:AB_2491019){#intref0315}VRC01i (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840664](ncbi-n:KP840664){#intref0320}, [KP840695](ncbi-n:KP840695){#intref0325}VRC01h (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840663](ncbi-n:KP840663){#intref0330}, [KP840694](ncbi-n:KP840694){#intref0335}VRC01f (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840661](ncbi-n:KP840661){#intref0340}, [KP840692](ncbi-n:KP840692){#intref0345}VRC01e (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840660](ncbi-n:KP840660){#intref0350}, [KP840691](ncbi-n:KP840691){#intref0355}VRC01j (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840665](ncbi-n:KP840665){#intref0360}, [KP840696](ncbi-n:KP840696){#intref0365}VRC01d (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840659](ncbi-n:KP840659){#intref0370}, [KP840690](ncbi-n:KP840690){#intref0375}VRC07e (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840669](ncbi-n:KP840669){#intref0380}, [KP840700](ncbi-n:KP840700){#intref0385}VRC07f (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840670](ncbi-n:KP840670){#intref0390}, [KP840701](ncbi-n:KP840701){#intref0395}VRC07d (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840668](ncbi-n:KP840668){#intref0400}, [KP840699](ncbi-n:KP840699){#intref0405}NIH45-46 (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib60])GenBank: [HE584543](ncbi-n:HE584543){#intref0410}, [HE584544](ncbi-n:HE584544){#intref0415}; RRID: [AB_2491035](nif-antibody:AB_2491035){#intref0420}VRC07c (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840667](ncbi-n:KP840667){#intref0425}, [KP840698](ncbi-n:KP840698){#intref0430}VRC07b (VRC01 lineage mAb isolated from individual NIH45)Produced in house ([@bib72])GenBank: [KP840666](ncbi-n:KP840666){#intref0435}, [KP840697](ncbi-n:KP840697){#intref0440}VRC01 V.Rev[@bib70]See [Table S1](#mmc1){ref-type="supplementary-material"}VRC03 V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}VRC18b V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}3BNC60 V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}3BNC117 V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}12A12 V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}VRC20 V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}VRC23 V.RevThis paperSee [Table S1](#mmc1){ref-type="supplementary-material"}VRC01 VJ.Rev (aka VRC01 GL.Rev)[@bib31]See [Table S1](#mmc1){ref-type="supplementary-material"}VRC03 VJ.Rev (aka VRC03 GL.Rev)[@bib31]N/AVRC06 VJ.Rev (aka VRC06 GL.Rev)[@bib31]N/ANIH-45-46 VJ.Rev (aka NIH45-46 GL.Rev)[@bib31]N/A**Bacterial and Virus Strains**HIV-1 MN.3 pseudovirusProduced in house.Los Alamos Databases. HIV sequence database Accession number [HM215430](ncbi-n:HM215430){#intref0445}HIV-1 strain BJOX2000 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain CE1176 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain X1632 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain X2278 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain 398F1 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain 25710 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain CNE8 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain TRO11 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain 246F3 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain CE0217 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain CH119 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670HIV-1 strain CNE55 pseudovirusProduced in house ([@bib14])NIH AIDS Reagent Program Cat. No. 12670**Biological Samples**PBMCs from patient NIH45VRC/NIAIDN/A**Chemicals, Peptides, and Recombinant Proteins**Synthetic construct eOD-GT6-Avi-3C-His (eOD-GT6)Produced in house ([@bib65])GenBank: [KX527852](ncbi-n:KX527852){#intref0450}Synthetic construct delta_eOD-GT6-Avi-3C-His gene (eOD-GT6 KO)Produced in house ([@bib65])GenBank: [KX527853](ncbi-n:KX527853){#intref0455}Synthetic construct eOD-GT8-Avi-3C-His gene (eOD-GT8) (monomer)Produced in house ([@bib65])GenBank: [KX527855](ncbi-n:KX527855){#intref0460}Synthetic construct delta_eOD-GT8-Avi-3C-His (eOD-GT8 KO) (monomer)Produced in house ([@bib65])GenBank: [KX527856](ncbi-n:KX527856){#intref0465}Synthetic construct clone 426c-degly3.coreE-AviHis mutant envelope glycoprotein (TM1ΔV1-3)Produced in house ([@bib65])GenBank: [KX518319](ncbi-n:KX518319){#intref0470}Synthetic construct clone 426c-degly3.D279K/D368R.coreE-AviHis mutant envelope glycoprotein (TM1ΔV1-3 KO)Produced in house ([@bib65])GenBank: [KX518320](ncbi-n:KX518320){#intref0475}Synthetic construct chimeric gp120 core C13.G3 precursor (C13)Produced in house ([@bib65])GenBank: [KX462845](ncbi-n:KX462845){#intref0480}Synthetic construct chimeric gp120 core C13.G3 D279K precursor (C13 KO)Produced in house ([@bib65])N/AeOD-GT8 (heptamer)Produced in house.N/AeOD-GT8 (24-mer)Produced in house.N/ATM4ΔV1-3 (monomer)Produced in house ([@bib46])N/ATM4ΔV1-3 KO (monomer)Produced in house ([@bib46])N/ATM4ΔV1-3 (heptamer)Produced in house ([@bib46])N/ATM4ΔV1-3 D368R/E370A (heptamer)Produced in house ([@bib46])N/ATM4ΔV1-3 (24-mer)Produced in house ([@bib46])N/ATM4ΔV1-3 D368R/E370A (24-mer)Produced in house ([@bib46])N/ABG505 SOSIP v4.1-GT1Produced in house ([@bib47])N/ABG505 SOSIPProduced in house ([@bib47])N/AResurfaced Core Protein-3 (RSC3)Produced in house ([@bib70])N/AResurfaced Core Protein-3 delta 371I/P363NProduced in house ([@bib70])N/AUBE3AUBPBioCat No. K1410SureBlue Reserve TMBKPLCat. No. 53-00-03Jo-1 antigenImmunoVisionCat. No. JO1-3000nRNP Complex (Sm/RNP)ImmunoVisionCat. No. SRC-3000Scl-70 antigenImmunoVisionCat. No. SCL-3000Smith (Sm) antigenImmunoVisionCat. No. SMA-3000SSA (Ro) antigenImmunoVisionCat. No. SSA-3000SSB (La) antigenImmunoVisionCat. No. SSB-3000Centromere protein BProspecCat. No. PRO-390Deoxyribonucleic Acid, Calf Thymus SourceWorthingtonCat. No. LS002105Poly-lysineSigma AldrichCat. No. P6285**Critical Commercial Assays**ExpiFectamine 293 transfection kitThermoFisher ScientificCat. No. A14525FLIPR Calcium 6 Assay KitMolecular DevicesCat. No. R8190ANA HEp-2 test systemZeuss ScientificCat. No. FA2400ProtoArray Human Protein MicroarrayInvitrogenCat. No. PAH0525101**Deposited Data**VRC01 UCAGenBankMK032222, MK032237DH651.1 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032223, MK032238DH651.2 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032224, MK032239DH651.3 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032225, MK032240DH651.4 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032226, MK032241DH651.5 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032227, MK032242DH651.6 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032228, MK032243DH651.7 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032229, MK032244DH651.8 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032230, MK032245DH651.9 (VRC01 lineage mAb isolated from individual NIH45)GenBankMK032231, MK032246**Experimental Models: Cell Lines**MS40L cells[@bib42]N/ARamos cells[@bib4]ATCC CRL-1596TZM-bl cellsDr. John C. Kappes and Dr. Xiaoyun WuNIH AIDS Reagent Program Cat. No. 8129**Oligonucleotides**gggcttctggatatgaatttattgattgttatctaaa\
ttggattcgtctggccccThermoFisherN/Aggatatgaatttattgattgtacgatgaattggattc\
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Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Mattia Bonsignori (<mattia.bonsignori@duke.edu>) and the Senior Author, Barton F. Haynes (<barton.haynes@duke.edu>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human specimens {#sec4.3.1}

The peripheral blood mononuclear cells (PBMCs) used to isolate mAbs DH651.1 through DH651.9 were collected from NIH donor 45, from whom the VRC01 lineage was isolated ([@bib70]). Donor 45 is a male diagnosed with a clade B virus infection in 1990. He enrolled in a clinical protocol approved by the Institutional Review Board at the National Institute of Allergy and Infectious Diseases in 1995. PBMCs used in this study were collected in 2008, 18 years after diagnosis. Donor 45 is a slow progressor who, from 1995 to 2009, maintained CD4^+^ T cell counts over 500 cells/μl and plasma HIV-1 RNA values less than 17,000 copies/ml without ever receiving antiretroviral treatment ([@bib70], [@bib72]).

### Cell lines {#sec4.3.2}

MS40L is a cell line derived from a murine stem cell line (MS5) to express low levels of cell surface human CD40L. MS40L cells have been widely used to support robust B cell growth *in vitro* in presence of additional stimulants. Information on the sex of the mouse from which the MS5 cell line was derived is not available.

TZM-bl is a HeLa cell line that expresses CD4 receptor and both CXCR4 and CCR5 chemokine co-receptors; TZM-bl cells also express luciferase and β-galactosidase under the control of the HIV-1 promoter, hence are useful to assay *in vitro* HIV-1 infection. The HeLa cell line was derived from cancerous epithelial cells isolated from the cervix of a patient with cervical adenocarcinoma.

Expi293F cells (ThermoFisher) are human cells derived from the 293F cell line, which were, in turn, derived from transformed human embryonal kidney (HEK) cells. HEK293 is a hypotriploid cell line containing three copies of X chromosomes and no evidence of Y chromosome-derived sequences, suggesting that the fetus from which they were derived was female. Expi293F cells were transfected with IgH and IgL-encoding plasmids to produce recombinant monoclonal antibodies.

Ramos is a cell line derived from human lymphoblasts of a young male with Burkitt's lymphoma: Ramos cells were stably transfected to express IgM BCRs of interest.

The human epithelial type 2 (HEp-2) cell line, initially considered to originate from a human laryngeal carcinoma, has been later authenticated to derive from HeLa cells: HEp-2 cells enable the identification of antinuclear antibodies.

Method Details {#sec4.4}
--------------

### Isolation of VRC01 lineage antibodies {#sec4.4.1}

The HIV-1 Resurfaced Core Protein-3 (RSC3) ([@bib70]) was produced and used in flow cytometry on 39 million PBMCs collected from donor 45 using a two-color technique as described ([@bib22]). A total of 1,917 RSC3-positive memory B cells were cultured as described ([@bib8]) with the following modifications: After overnight incubation in bulk in presence with EBV, memory B cells were plated at limiting dilution (0.8 cells/well) in culture wells containing MS40L feeder cells ([@bib42]) irradiated (9,000 cGy) and plated at a concentration of 5,000 cells/well. After 2 weeks, cell culture supernatants were screened for neutralization of the MN.3 HIV-1 strain using the tzm-bl cell-based neutralization assay ([@bib6], [@bib48]), and binding to consensus S gp140 Env, UBE3A, RSC3 and RSC3Δ371I/P363N ([@bib41], [@bib70]). VRC01 lineage mAbs DH651.1 through DH651.9 were isolated from culture supernatants that displayed differential binding of RSC3 and RSC3Δ371I/P363N; of them, UBE3A reactivity was detected in 3 cultures, and 8 cultures neutralized \> 75% MN.3 infectivity.

### Antibody production {#sec4.4.2}

Immunoglobulin genes of mAbs DH651.1 through DH651.9 were amplified from RNA from isolated cells, expression cassettes made, and mAbs expressed as described ([@bib19], [@bib39]). Heavy chain plasmids were co-transfected with appropriate light chain plasmids at an equal ratio in Expi293 cells using ExpiFectamine 293 transfection reagents (Thermo Fisher Scientific) according to the manufacturer's protocols and using the enhancer provided with the kit. Transfected cultures were incubated at 37°C 8% CO~2~ for 2-6 days, harvested, concentrated and incubated overnight with Protein A beads at 4°C on a rotating shaker before loading the bead mixture in columns for purification; following PBS/NaCl wash, eluate was neutralized with trizma hydrochloride and antibody concentration was determined by Nanodrop. Purified antibodies were tested in SDS-Page Coomassie and western blots, and stored at 4°C. Thirty-six additional monoclonal antibodies in the VRC01 lineage for which naturally paired IgH and IgL sequences were previously described ([@bib38], [@bib60], [@bib70], [@bib72]) were produced using the same method. Amino acid positions are expressed using the Kabat numbering system ([@bib34]). Alignments were performed using Bioedit and EMBOSS Water. (<https://www.ebi.ac.uk/Tools/psa/emboss_water/>).

### Inference of the VRC01 clonal history including UCAs and unobserved intermediates {#sec4.4.3}

The hybrid method used to infer the VRC01 UCA and the unobserved IAs is as follows. First, we use our software Cloanalyst ([@bib35], [@bib40]) to verify the clonal relatedness of the candidate members. Briefly, Cloanalyst computes the summed log-marginal likehoods over subsets of the candidate sequences, each subset treated as an independent clone, and identifies that subset that maximizes that quantity. That subset, in this case, was the complete set, indicating that all observed members belong to the same clone.

We then performed a multiple sequence alignment using Clustal Omega ([@bib62]), and after manual adjustment of the resulting gaps to minimize the number of columns containing gaps, we removed all columns containing gaps. We then used PhyML ([@bib23]), provided online by the server at <http://www.phylogeny.fr/>, using the HKY85 substitution model, to infer the maximum likelihood trees for the heavy- and light-chain collections separately. We performed 100 bootstrap replicates to identify weakly supported branches. We then concatenated the heavy- and light-chain sequences from each observed antibody, leaving the inferred gaps intact, and used Phylip's DNAML ([@bib18]) to estimate the maximum likelihood tree common to both heavy and light chains. We used five classes of mutation rates in the discrete-gamma model of rate variation, and a base rate in which the heavy chain mutates at twice the rate of the light chain. We then computed the UCA and the unobserved IAs using Cloanalyst, performing a Bayesian average over all viable combinations of rearrangement parameters with prior distributions on recombination parameters obtained using data from an independent study. We then manually readjusted the precise locations of the indels to account for the locations of the recombination points in the most-probable gene segments involved in the UCA. We recomputed the joint maximum-likelihood tree and the heavy- and light-chain UCAs.

Cloanalyst estimates the expected error in each base of the inferred UCAs conditional on the phylogenetic tree and on the multiple sequence alignment, i.e., the positions of the indels. Since in this case, both the phylogenetic tree and the multiple sequence alignment are subject to non-negligible uncertainty, the estimates of the expected errors should be regarded as minimum estimates. If we were able to average over trees and alignments as well, these expected errors might be substantially larger.

### Surface Plasmon Resonance Affinity and Kinetics Measurements {#sec4.4.4}

Dissociation (K~D~) and rate constants (*k*~*on*~, *k*~*off*~) were measured using the Biacore S200 (GE Healthcare). CM5 sensor chips (or CM3 for SOSIP proteins) were used to directly immobilize antibodies to a level of approximately 2000-3000RU. Proteins were diluted from 0.5nM-4000nM (0.1 μg/mL-150 μg/mL) in HBS-EP+ 1 × buffer and then injected over the antibody immobilized surfaces for 5 min at 50 μL/min. The 5 min analyte injection was followed by a 10 min dissociation period with buffer wash and then a 20 s injection pulse of Glycine pH2.0 for regeneration. Kinetics results were analyzed using the Biacore S200 Evaluation Software (GE Healthcare). A negative control antibody (Ab82) and buffer binding were used for double reference subtraction to account for non-specific binding and signal drift. Subsequent curve fitting analysis was performed using a 1:1 Langmuir model with a local R~max~ and the reported rate constants are representative of 2 measurements. Exceptions to the above curve fitting model included some BG505 trimeric protein interactions, which were analyzed using the bivalent analyte model and for some core protein interactions, which were analyzed using the heterogeneous ligand model.

### Biolayer Interferometry (BLI) {#sec4.4.5}

BLI assays were performed on the Octet Red instrument at 30°C with shaking at 1,000 RPM. Anti-Human IgG Fc capture (AHC) biosensors (Fortebio) were immersed into PBS containing 20μg/ml VRC01 UCA IgG for 240 s. A baseline signal was recorded for 1 min in kinetics buffer (KB: 1X PBS, 0.01% BSA, 0.02% Tween 20, and 0.005% NaN~3~, at pH 7.4). Sensors were then immersed into solutions containing 2μM of monomeric, heptameric, or icositetrameric eOD-GT8, eODGT8 D279K/D368R, 426c TM4ΔV1-3 or 426c TM4ΔV1-3 D368R/E370A glycoprotein for 300 s to measure association, followed by immersion in KB for 300 s to measure dissociation. All measurements of antibody binding were corrected by subtracting the signal obtained from simultaneous traces performed with the corresponding envelopes in the absence of antibody, using PBS only.

### Calcium Flux Measurement {#sec4.4.6}

Proteins expressed with a C-terminal avidin tag sequence (GLNDIFEAQKIEWHE) were biotinylated with the BirA biotin-protein ligation kit (Avidity) and agitated at 900 rpm 30°C for 5 h. The biotinylated protein was then transferred to a 0.5mL 3kDa MWCO spin column (Amicon) and excess biotin was removed with five washes of PBS (GIBCO). Protein tetramers were formed at a 4:1 molar ratio of protein to streptavidin (Invitrogen). To maximize streptavidin site occupancy 1/5 of the streptavidin volume was added 5 × every 15 min. Molarity was calculated based upon the number of moles of protein added to the tetramer reaction. Cultured stably transfected Ramos cell lines ([@bib4], [@bib67]) were passaged 1:10 four days preceding calcium flux experiments. On the day of the experiment cells with \> 95% viability were resuspended at 1x10^6^ cells/mL in 2:1 ratio of RPMI media (GIBCO) + FLIPR Calcium 6 dye (Molecular Devices). Cells were plated in a U-bottom 96 well tissue culture plate (Costar) and incubated at 37°C 5% CO~2~ for 2 h. In a black clear bottom 96 well plate (Costar) containing 50 μLs RPMI media (GIBCO) + FLIPR Calcium 6 dye (Molecular Devices) (2:1 ratio) either 0.1nMoles of proteins or 50 μg/mL of Anti-human IgM F(ab')~2~ (Jackson Immuno) were added (based on a 100 μL volume). Using a FlexStation 3 multi-mode microplate reader (Molecular Devices) 50 μL of supernatant containing cells were transferred into the 50 μL of media containing protein or Anti-human IgM F(ab')~2~ (Jackson Immuno) and continuously read for 5 min. Relative fluorescent value units were background subtracted and the data expressed as percentage of the IgM maximum signal (% IgM~max~).

### Assessment of virus neutralization {#sec4.4.7}

Antibody neutralization was measured in TZM-bl cell-based assays ([@bib48]). Neutralization breadth was assessed using a 12-virus panel that recapitulates global HIV-1 diversity ([@bib14]). Data were calculated as a reduction in luminescence units compared with control wells, and reported as IC~50~ or IC~80~ in μg/ml.

### Immunogens {#sec4.4.8}

The following immunogens were produced at the Duke Human Vaccine Institute and at the VRC/NIAID with plasmids prepared at the VRC/NIAID: eOD-GT6 (KX527852) ([@bib65]), eOD-GT6 KO (KX527854) ([@bib65]), eOD-GT8 (KX527855) ([@bib65]), eOD-GT8 KO (KX527856) ([@bib65]), TM1ΔV1-3 (KX518319) ([@bib65]), TM1ΔV1-3 KO (KX518320) ([@bib65]), C13 (KX462845) ([@bib65]) and C13 KO was made by introducing the D279K mutation in C13. TM4ΔV1-3 and TM4ΔV1-3 KO were produced at the Vaccine and Infectious Disease Division of the Fred Hutchinson Cancer Research Center as described ([@bib46]). BG505 SOSIP v4.1-GT1 and wild-type BG505 SOSIP were produced at the Department of Medical Microbiology of the Academic Medical Center (University of Amsterdam) as described ([@bib47]).

### Molecular Dynamics Simulation {#sec4.4.9}

A gp120 portion from the crystal structure of the VRC08 Fab structure in complex with HIV-1 strain Q842.d12 gp120 (PDB: [4XMP](pdb:4XMP){#intref0575}) was aligned with each gp120 of the crystal structure of JR-FL SOSIP trimer in complex with PGT122, 35O22 and VRC01 (PDB: [5FYK](pdb:5FYK){#intref0580}) after addition of missing loops in the JR-FL structure using Modeler ([@bib58], [@bib64], [@bib72]). The Q842.d12 gp120 portions were removed along with all antibodies excluding VRC08. The JR-FL structure was then glycosylated with Man5 using Rosetta according to glycan positions determined using the LANL N-GlycoSite web server. The glycosylated timer-antibody complex was then minimized in vacuum using the CHARMM36 force field for 25,000 steps with the protein backbone atoms fixed using NAMD 2.12 ([@bib52]). The minimized complex was then solvated in TIP3P water molecules with the addition of neutralizing NaCl brought to an effective concentration of 0.150M using VMD to give a total system size of 890,399 atoms ([@bib28], [@bib33]). The solvent protein system was then minimized for 1,500 steps followed by 50 ps of dynamics using a 1 fs time step with constraints on the protein backbone atoms using a constraint exponent of two. The system was then minimized for 1,500 steps followed by heating from 50 K to 300 K with the constraints removed followed by 250 ps of dynamics at 300K. The protein-solvent system was then simulated unconstrained for a total of 50 ns (ns) using a 2fs time step with hydrogens constrained using the SHAKE algorithm ([@bib56]). The temperature was maintained using Langevin dynamics with a damping coefficient of 1/ps with the pressure maintained at 1 atm using the Nosé-Hoover Langevin position method with a period of 100 fs and decay of 50 fs ([@bib44]). Electrostatic and van der Waals interaction calculations were cut off at 12 Å using switching functions beginning at 10 Å with long range electrostatic calculations handled using the particle mesh Ewald method with periodic boundary conditions ([@bib17]). Visualization and analysis of the resulting trajectories was performed using VMD and plugins therein. Specifically, the RMSD of the CDR H3, sequence GRSCCGGRRHCNGADCFNWDFQH, was determined for each of the three bound VRC08 Fabs using the RMSD trajectory tool ([@bib28]).

### HEp-2 Cell Staining {#sec4.4.10}

Indirect immunofluorescence binding of mAbs to HEp-2 cells (Zeuss Scientific) was performed as previously described ([@bib7], [@bib26]). Briefly, 20μl of antibody at 50μg/ml was aliquoted onto a predetermined spot on the surface of a slide (ANA HEp-2 kit). After incubation for 20 min at room temperature and washes, 20μl of secondary antibody (goat anti-human Ig FITC at 30μg/ml; Southern Biotech) was added to each spot and incubated in a humid chamber for 20 min in the dark. After washing and drying, a drop of 50% glycerol was added to each spot, and the slide was covered with a 24- by 60-mm coverslip. Images were taken on an Olympus AX70 instrument with a SpotFlex FX1520 CCD and with a UPlanFL 40× 0.75-NA objective at 25°C in the FITC channel using SPOT software. All images were acquired for 12s. Image layout and scaling were performed with Adobe Photoshop without image manipulation.

### Protein Array {#sec4.4.11}

MAbs were screened for binding on protein microarrays (ProtoArray) (PAH0525101; Invitrogen) pre-coated with 9,400 human proteins in duplicate and screened following manufacturer's instructions and as previously described ([@bib41]). Briefly, after blocking, the microarray was incubated on ice with 2 μg/ml of mAbs or isotype control 151K for 90 min. Ab binding to array protein was detected with 1 μg/ml of Alexa Fluor 647-labeled anti-human IgG (Invitrogen) secondary Ab. Microarrays were scanned using a GenePix 4000B scanner (Molecular Devices) at a wavelength of 635 nm, with 10-μm resolution, using 100% power and 600 gain. Fluorescence intensities were quantified with GenePix Pro 5.0 program (Molecular Devices) using lot-specific protein location information provided by the microarray manufacturer.

### Indirect-binding ELISA {#sec4.4.12}

ELISAs were performed as previously described ([@bib9], [@bib8]). Briefly, for biotinylated proteins (i.e., biotinylated avi-tagged RSC3, RSC3Δ371I/P363N and consensus S gp140 Env), plates were coated with 2 μg streptavidin, incubated at RT for 2h and blocked either for 1h at RT or overnight at 4°C. Biotinylated proteins were added (2 μg/ml) for 30 mins at RT or overnight at 4°C. The autoantigen UBE3A (UBPBio catalog \# K1410) was directly coated on the plates at 6ug/ml, incubated at RT for 2h and blocked overnight at 4°C. Culture supernatants were added at a 1:3 dilution in assay diluent, whereas purified antibodies were titrated starting at 100 μg/ml (1:3 dilutions, 11 steps), incubated for 1h and 45 mins at RT. After washing, HRP-conjugated goat anti-human IgG antibody (Jackson ImmunoResearch) was added at lot-specific predetermined optimal concentration for 1h; after washing, plates were developed using SureBlue Reserve TMB (KPL, Gaithersburg, MD) equilibrated at RT. Development was stopped after 10 min and plates were read at 450nm and 650nm (for background subtraction) wavelengths in a SpectraMax 384PLUS reader (MolecularDevices, Sunnyvale, CA).

Purified histones (whole), Jo-1, RNP/Sm, Scl-70, Sm, SSA (Ro), SSB (all from ImmunoVision) and centromere B (Prospec) were coated in sodium bicarbonate solution overnight at 4°C at optimal concentrations determined by lot-specific checkerboard with human-derived positive controls (ImmunoVision). For DNA, plates were pre-coated with 10μg/ml poly-lysine (Sigma-Aldrich) overnight at 4°C, washed 1 × with wash buffer (PBS/0.05% tween 20) and followed with DNA (LS002195, Worthington) at 20 μg/ml in saline sodium citrate buffer for 1h as determined in optimization assays. All plates were washed 1 × , blocked with 3%BSA/PBS for 1 h at RT and flicked/tapped dry. Antibodies, serially diluted in assay diluent (1% BSA/PBS/0.05% Tween-20) were incubated for 45 min followed by 2 × wash. Secondary antibody was added for 30 min, washed 4 × followed by TMB substrate (Sera Care Life Sciences). Reactions were stopped after 10 min.

### Antibody site-directed mutagenesis {#sec4.4.13}

Site-directed mutagenesis of antibody genes was performed using the Quikchange II lightening multi-site-directed mutagenesis kit following manufacturer's protocol (Agilent). Mutant plasmid products were confirmed by single-colony sequencing. Primers used for introducing mutations were: VRC01 T33Y: gggcttctggatatgaatttattgattgttatctaaattggattcgtctggcccc; VRC01 L34M: ggatatgaatttattgattgtacgatgaattggattcgtctggccccc. VRC01, VRC02, DH651.2 and DH651.4 T33L/L34M double mutants were expressed directly from plasmids containing the double mutations, without site-directed mutagenesis. The probability of the Y33T and M34M mutations were determined using the computational program [A]{.ul}ntigen [R]{.ul}eceptor [M]{.ul}utation [A]{.ul}nalyzer for [D]{.ul}etection of [L]{.ul}ow [L]{.ul}ikelihood [O]{.ul}ccurrences (ARMADiLLO) ([@bib69]).

### Logo plots {#sec4.4.14}

Logo plots were generated using the Los Alamos HIV database web interfaces (<https://www.hiv.lanl.gov>, version Dec. 2015, HEATMAP and Analyze Align).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For associations between neutralization breadth or potency and clade membership of VRC01 lineage mAbs ([Figure 5](#fig5){ref-type="fig"}), the Kruskal-Wallis and Dunn's multiple comparison tests were applied (GraphPad Prism version 7.03). Significance was evaluated at the alpha 0.05 level.

For associations between neutralization breadth or potency and auto-/polyreactivity ([Figures 7](#fig7){ref-type="fig"}B and 7C) and between UBE3A binding and presence of the ^33^TL^34^ motif in IgH ([Figure S6](#mmc1){ref-type="supplementary-material"}A), the Mann-Whitney U-test method was applied (GraphPad Prism version 7.03). Significance was evaluated at the alpha 0.05 level.

Correlations between levels of neutralization breadth or potency and polyreactivity ([Figures 7](#fig7){ref-type="fig"}D and 7E) (n = 43) were analyzed by Spearman correlation and significance was evaluated at the alpha 0.05 level.

Data and Software Availability {#sec4.6}
------------------------------

The IgH and IgL variable region sequences of VRC01 UCA and DH651.1 through DH651.9 monoclonal antibodies have been deposited in GenBank with accession numbers MK032222 through MK032231 and MK032237 through MK032246.
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